For instance, the simultaneous targeting of BRD4 (by BETi) and oncogenic pathways, such as WNT and MAPK, in CRC inhibits the oncogenic expression of MYC and decreases the risk of tumour resistance [141]. The gene discussed is BRD4; the disease is neoplasm.